New drugs new adverse effects: Neurology and immune checkpoint inhibitors ,
Posted on June 29, 2020 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Improving clinical trials in ALS ,
Posted on December 12, 2019 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Sporadic Creutzfeldt-Jakob disease: beyond central nervous system dysfunction ,
Posted on May 15, 2019 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Primary lateral sclerosis and progressive muscular atrophy as a multidomain brain disorder ,
Posted on February 11, 2019 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Inflammatory neuropathies with paranodal antibodies: more than just IgG ,
Posted on November 19, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
“No evidence of disease activity” does not mean no evidence of brain deterioration ,
Posted on September 7, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Novel motor mapping techniques of the spinal cord: why does it matter? ,
Posted on July 8, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Uncovering the clinicopathological spectrum in neuropathy associated with anti-MAG antibodies ,
Posted on May 20, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Chitotriosidase, neuroinflammation and ALS ,
Posted on April 11, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
Atrial fibrillation and white matter hyperintensities: more than just coincidence ,
Posted on January 14, 2018 by Dr José Manuel Matamala, JNNP web editor. in Uncategorized
